EPIGRAL1,149.50

Epigral Limited

· Chemicals
₹ CrorePeersYASHOGUJALKALIFCLFOSECOINDVISHNUTATVAGALAXYSURFJUBLCPLMcap ₹4,959 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)89.58107.0985.3685.36
Receivable Days (DSO)33.8233.2560.1660.16
Payable Days (DPO)56.3051.2563.5959.15
Cash Conversion Cycle (days)67.1089.0981.9386.37
Working Capital Turnover-6.959.0321.7422.59
Asset Turnover0.690.810.720.72
Cash Conversion (CFO/Net Income)2.031.231.311.31
CFO/EBITDA0.830.620.770.77
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.